Impact BioMedical completes 1-for-12.62 reverse stock split

Impact BioMedical Inc. (NYSE American: IBO) completed a one-for-12.62 reverse stock split of its common stock on September 23, 2026. The company disclosed the action in a Form 8-K filed with the Securities and Exchange Commission on October 9, 2026, after a clerical processing delay at the Nevada Secretary of State's office prevented the receipt of the file-stamped Certificate of Amendment until October 6, 2026.

The Board of Directors initially approved the proposal for a reverse stock split on November 24, 2025, subject to shareholder approval. Shareholders voted in favor of the measure on December 30, 2025, authorizing a ratio between 1-for-12.48 and 1-for-50. The company's Chief Executive Officer retained discretion to determine the specific ratio within that authorized range. Impact BioMedical selected a 1-for-12.62 ratio for the final adjustment.

The split became effective at 12:01 A.M. EST on September 23, 2026. At that time, every 12.62 shares of issued and outstanding pre-split common stock were automatically combined into one share of post-split common stock. The company began trading on a split-adjusted basis on the same day under its existing ticker symbol IBO and a new CUSIP number, 45259L304, on the New York Stock Exchange American.

The reverse stock split reduced the number of issued and outstanding shares from approximately 107.8 million to approximately 8.6 million. The action did not change the authorized number of shares, the par value of the common stock or preferred stock, or any voting rights associated with the common stock. No fractional shares were issued; stockholders entitled to a fractional share received one full post-split share in lieu of the fraction.

Equiniti Transfer & Trust Company serves as the transfer agent and exchange agent for the split. Registered stockholders holding shares in book-entry form and those holding shares through brokers, banks, or trusts did not need to take action to receive their adjusted positions, subject to individual broker processes. The company stated it has been in contact with the New York Stock Exchange American regarding the delayed filing.

Frank D. Heuszel, Chief Executive Officer of Impact BioMedical Inc., signed the Form 8-K on behalf of the registrant on October 9, 2026. The filing includes a Certificate of Amendment to the Amended and Restated Articles of Incorporation as Exhibit 3.1.